The recent buying activity by director Bradford T. Whitmore suggests an increase in internal confidence regarding Ultralife Corp (NASDAQ:ULBI). Mr. Whitmore, who is both a director and holds a ten percent ownership stake in the company, executed several purchases of common stock between May 21 and May 26, 2026. These aggregated transactions resulted in an acquisition of 108,878 shares, valued at $715,313.
The purchase prices for these shares varied across the reported period, ranging from a low of $6.1343 to a high of $6.8137 per share. This insider accumulation takes place while ULBI stock is trading near $6.86, representing gains exceeding 7% over the past week.
Detailed Breakdown of Insider Transactions
Mr. Whitmore's buying spree was staggered across multiple days:
- May 21: He acquired 32,876 shares, based on a weighted average price of $6.1343 per share. The individual transaction prices recorded for this day spanned from $5.97 to $6.359.
- May 22: An additional 8,700 shares were purchased at a weighted average price of $6.3295. Individual transactions on this date ranged between $6.2953 and $6.3995.
- May 26: The final reported purchase involved 67,302 shares, with a weighted average cost of $6.8137 per share. Prices for these shares varied from $6.6399 to $6.9499.
It is important to note that all these purchases were executed indirectly through Whitmore Holdings, LLC. As the manager of Whitmore Holdings, LLC (and also serving as trustee of Bradford Whitmore Trust, which is the sole member of Whitmore Holdings, LLC), Mr. Whitmore is considered an indirect beneficial owner of this newly acquired stock.
Current Ownership Structure
Following these recent transactions, the total holding in Whitmore Holdings, LLC stands at 2,050,637 shares of Ultralife Corp common stock. Furthermore, Mr. Whitmore maintains a direct personal holding of 205,915 shares and possesses an additional indirect ownership stake of 4,452,283 shares through SUNRAY I, LLC, where he occupies the role of manager.
The timing of this substantial insider buying contrasts with ULBI's recent financial disclosures. Ultralife Corporation recently released its Q1 2026 earnings report, which did not meet expectations set by analysts. The company announced a net loss of $0.03 per share, falling significantly short of the anticipated $0.15 per share. Furthermore, revenue also underperformed projections, reaching $47.4 million compared to the expected $52.4 million.
These financial results signal a challenging quarter for Ultralife Corporation and have prompted increased scrutiny regarding its market standing. The combination of the earnings miss and the decline in revenue has heightened concerns among investors. Consequently, analysts and investors are closely monitoring these developments to ascertain their potential impact on the company's future profitability and overall valuation.
Risks
- Disappointing Q1 2026 financial results, including a net loss of $0.03 per share (vs. expected $0.15).
- Revenue coming in at $47.4 million, which is below the projected $52.4 million.
- The need for investors to closely monitor future developments to understand potential impact on earnings.
More from Insider Trading